New liposomal drug combo aims to boost lymphoma remission
NCT ID NCT06594640
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new combination of drugs for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The experimental drug is a liposomal form of mitoxantrone, given with standard chemotherapy and rituximab. The trial has two parts: first, finding the safest dose, then checking how well it works. About 108 adults with untreated DLBCL will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mitoxantrone hydrochloride liposome combined with cyclophosphamide, vincristine, prednisone, and rituximab
What this could lead to
If successful, this could offer a more effective and possibly safer first-line treatment for diffuse large B-cell lymphoma, improving remission rates.
What could go wrong
This is an early-phase trial (phase I/II) with only 108 participants, so results may not apply broadly. The new drug combination may cause unexpected side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Disease Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact